Gynecologic Malignancies¶
Chapter 94 | Part 12: Endocrinology
KEY CLINICAL POINTS¶
- Ovarian cancer is the 5th leading cause of cancer death in women, with BRCA1/2 mutations significantly increasing risk.
- Cervical cancer is driven by HPV infection, with 90% of cases linked to HPV16 and HPV18.
- Testicular non-GCTs like seminomas and teratomas have distinct treatment protocols compared to germ cell tumors.
- Early detection via Pap smears and HPV testing is critical for cervical cancer prevention.
- PARP inhibitors are effective in BRCA-mutated ovarian cancers, improving survival outcomes.
1. DEFINITION & OVERVIEW¶
Gynecologic malignancies encompass cancers of the female reproductive system, including ovarian, cervical, endometrial, and gestational trophoblastic tumors. These cancers vary in etiology, pathophysiology, and treatment approaches. Key subtypes include epithelial ovarian cancer, germ cell tumors, and endometrial cancers, each with distinct clinical features and prognostic factors.
Table 94-1 Staging and Survival in Gynecologic Malignancies¶
| STAGE | OVARIAN | 5-YEAR SURVIVAL, % | ENDOMETRI AL | 5-YEAR SURVIVAL, % | CERVIX | 5-YEAR SURVIVAL, % |
|---|---|---|---|---|---|---|
| 0 | — | — | Carcinoma in situ | 100 | ||
| I | Confined to ovary | 88–95 | Confined to corpus | >90 | Confined to uterus | |
| II | Confined to pelvic organs | 70–80 | Involves corpus and cervix | ~75 | Invades beyond uterus but not to pelvic wall | 65 |
| III | Intra-abdomin al spread to omentum, diaphragm, or lymph nodes | 20–40 | Extends outside the uterus but not outside the true pelvis | 45–60 | Extends to pelvic wall and/or lower third of vagina, or hyd ronephrosis |
| STAGE | OVARIAN | 5-YEAR SURVIVAL, % | ENDOMETRI AL | 5-YEAR SURVIVAL, % | CERVIX | 5-YEAR SURVIVAL, % |
|---|---|---|---|---|---|---|
| IV | Spread outside abdominal cavity, parenchymal spread, and pleural effusion cytology | 10–20 | Extends outside the true pelvis or involves the bladder or rectum | ~20 | Invades mucosa of bladder or rectum or extends beyond the true pelvis | 7 |
1.1 Testicular Non-Germ Cell Tumors¶
Rare, including non-Hodgkin lymphoma, Leydig cell tumors, and mesothelioma. These tumors often present in older men and may metastasize to the testis. Treatment typically involves cisplatin-based chemotherapy.
1.2 Extragonadal Germ Cell Tumors¶
Originating outside the gonads, these tumors (e.g., mediastinal seminomas) have similar prognoses to gonadal counterparts. Treatment includes BEP chemotherapy, with surgical resection for residual disease.
1.3 Ovarian Cancer¶
Most common gynecologic malignancy, with serous tumors being the most aggressive. Staging (Table 94-1) and molecular subtypes (e.g., IDH-mutant vs. IDH-wild-type) guide treatment.
2. EPIDEMIOLOGY¶
Ovarian cancer incidence peaks in women aged 55–75, with 1 in 72 women developing it in their lifetime. Cervical cancer is the second most common malignancy in women globally, with 90% of cases linked to HPV. Risk factors include age, parity, smoking, and family history of BRCA mutations.
2.1 Ovarian Cancer¶
Incidence peaks in 55–75 years. Familial risk is significant in BRCA1/2 carriers, with 4% annual risk of endometrial cancer. Lynch syndrome (MLH1, MSH2 mutations) increases risk of endometrioid endometrial carcinoma.
2.2 Cervical Cancer¶
Global incidence ~570,000 new cases/year. Risk factors include early sexual debut, multiple partners, smoking, and HPV infection. HPV16/18 account for ~70% of cases.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Ovarian cancer is driven by mutations in TP53, BRCA1/2, and PI3K/AKT pathways. Cervical cancer is caused by persistent HPV infection, leading to E6/E7 oncoprotein expression. Testicular non-GCTs often involve chromosomal abnormalities like 12p amplification.
3.1 Ovarian Cancer¶
Type 1 (low-grade) tumors have mutations in KRAS, BRAF, and PTEN; Type 2 (high-grade) show TP53 and BRCA1/2 mutations. Molecular subtypes include serous, endometrioid, and clear cell variants.
3.2 Cervical Cancer¶
HPV E6/E7 proteins inactivate p53 and pRb, leading to uncontrolled cell proliferation. High-risk HPV types (16, 18, 31, 33, 35, 52, 58) are implicated in 90% of cases.
4. CLINICAL FEATURES¶
Symptoms vary by tumor type. Ovarian cancer presents with bloating, pelvic discomfort, and ascites. Cervical cancer may present with postcoital bleeding or abnormal Pap smears. Endometrial cancer often presents with postmenopausal bleeding.
4.1 Ovarian Cancer¶
Early symptoms include bloating, pelvic pain, and urinary/bowel changes. Advanced stages present with ascites, weight loss, and fatigue.
4.2 Cervical Cancer¶
Early stages may be asymptomatic. Advanced disease presents with vaginal bleeding, pelvic pain, and lymphadenopathy. HPV testing and Pap smears are critical for early detection.
5. DIFFERENTIAL DIAGNOSIS¶
Conditions mimicking gynecologic cancers include endometriosis, fibroids, and pelvic inflammatory disease. For ovarian masses, differential diagnoses include tubo-ovarian abscess and metastatic disease.
5.1 Ovarian Masses¶
Differential diagnoses include dermoid cysts, endometriomas, and fibromas. Imaging and biomarkers (CA-125) help distinguish benign from malignant lesions.
5.2 Cervical Lesions¶
Differential diagnoses include cervical polyps, infections, and atrophic changes. HPV testing and colposcopy are essential for accurate diagnosis.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic workup includes imaging (MRI/CT), lab tests (CA-125, HPV testing), and biopsy. For ovarian cancer, staging laparotomy and tumor markers guide management.
6.1 Ovarian Cancer¶
Imaging (CT/MRI) assesses staging. CA-125 levels correlate with disease burden. PET-CT may detect metastases. Biopsy confirms diagnosis.
6.2 Cervical Cancer¶
Pap smear and HPV testing are primary screening tools. Colposcopy with biopsy is used for high-risk lesions. Endocervical curettage may be required for advanced stages.
7. MANAGEMENT & TREATMENT¶
Treatment varies by tumor type. Ovarian cancer is managed with debulking surgery and platinum-based chemotherapy. Cervical cancer uses surgery, radiation, and targeted therapies.
7.1 Ovarian Cancer¶
Primary treatment: debulking surgery + platinum-based chemotherapy (carboplatin/paclitaxel). PARP inhibitors (olaparib) for BRCA-mutated tumors. Bevacizumab for advanced disease.
7.2 Cervical Cancer¶
Early-stage: surgery (hysterectomy) or radiation. Advanced disease: concurrent chemoradiation (cisplatin/5-FU). HPV vaccination prevents infection.
8. PROGNOSIS & COMPLICATIONS¶
5-year survival for ovarian cancer is 40–50% for stage III, with BRCA mutations improving outcomes with PARP inhibitors. Late effects of chemotherapy include infertility, secondary cancers, and cardiovascular risks.
8.1 Ovarian Cancer¶
Prognosis depends on stage, histology, and molecular markers. Late relapse is common, with resistance to platinum-based therapy.
8.2 Cervical Cancer¶
5-year survival ~90% for stage I, dropping to 15% for stage IV. Complications include infertility, pelvic pain, and recurrence after treatment.
9. SPECIAL CONSIDERATIONS¶
Pregnancy considerations, pediatric tumors, and survivorship care are critical. Fertility preservation is essential for young patients. Germline testing for BRCA mutations guides preventive strategies.
9.1 Fertility Preservation¶
Ovarian cancer survivors may require oophorectomy, necessitating fertility preservation via egg freezing or embryo cryopreservation.
9.2 Pediatric Tumors¶
Germinomas and medulloblastomas are common in children. Treatment includes surgery, radiation, and chemotherapy, with long-term follow-up for neurocognitive effects.
10. KEY POINTS & CLINICAL PEARLS¶
- BRCA1/2 testing is essential for ovarian cancer risk assessment and management. 2. HPV vaccination prevents cervical cancer. 3. PARP inhibitors improve survival in BRCA-mutated ovarian cancer. 4. Early detection via Pap smears and HPV testing is critical for cervical cancer prevention. 5. Multidisciplinary approach is vital for optimal outcomes in gynecologic malignancies.